Rituximab for HTLV-1-associated Myelopathy

NCT04004819 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

HTLV-1-associated Myelopathy

Interventions

DRUG: Rituximab

Sponsor

First Affiliated Hospital of Fujian Medical University